Loading...
VYNE Therapeutics Inc.
VYNE•NASDAQ
Healthcare
Biotechnology
$1.58
$0.21(15.34%)
VYNE Therapeutics Inc. (VYNE) Financial Performance & Statements
Review VYNE Therapeutics Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
18.16%
↑ 18.16%
Operating Income Growth
-49.15%
↓ 49.15%
Net Income Growth
-40.00%
↓ 40.004%
Operating Cash Flow Growth
-34.06%
↓ 34.06%
Operating Margin
-7414.88%
↓ 7414.88%
Gross Margin
65.95%
↑ 65.95%
Net Profit Margin
-6972.73%
↓ 6972.73%
ROE
-71.92%
↓ 71.92%
ROIC
-101.65%
↓ 101.65%
VYNE Therapeutics Inc. (VYNE) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for VYNE Therapeutics Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $84000.00 | $121000.00 | $198000.00 | $98000.00 |
| Cost of Revenue | $4000.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $80000.00 | $121000.00 | $198000.00 | $98000.00 |
| Gross Profit Ratio | $0.95 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $9.68M | $10.25M | $7.31M | $3.71M |
| SG&A Expenses | $3.17M | $2.96M | $3.29M | $3.77M |
| Operating Expenses | $12.85M | $13.21M | $10.59M | $7.48M |
| Total Costs & Expenses | $12.85M | $13.21M | $10.59M | $7.48M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $0.00 | $1.001M | -$777000.00 |
| EBITDA | -$12.77M | -$13.09M | -$9.39M | -$7.38M |
| EBITDA Ratio | -$152.02 | -$108.19 | -$47.45 | -$75.31 |
| Operating Income | -$12.77M | -$13.09M | -$10.40M | -$7.38M |
| Operating Income Ratio | -$152.02 | -$108.19 | -$52.51 | -$75.31 |
| Other Income/Expenses (Net) | $760000.00 | $934000.00 | $1.001M | $1.14M |
| Income Before Tax | -$12.01M | -$12.16M | -$9.39M | -$6.24M |
| Income Before Tax Ratio | -$142.98 | -$100.47 | -$47.45 | -$63.68 |
| Income Tax Expense | $4000.00 | $0.00 | $11000.00 | $8000.00 |
| Net Income | -$12.02M | -$12.16M | -$9.39M | -$6.24M |
| Net Income Ratio | -$143.12 | -$100.47 | -$47.45 | -$63.68 |
| EPS | -$0.28 | -$0.29 | -$0.22 | -$0.15 |
| Diluted EPS | -$0.28 | -$0.29 | -$0.22 | -$0.15 |
| Weighted Avg Shares Outstanding | $42.59M | $42.59M | $42.59M | $42.58M |
| Weighted Avg Shares Outstanding (Diluted) | $42.59M | $42.59M | $42.59M | $42.58M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan